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Abstract Earlier work in this laboratory and that carried out by others demonstrated that after a single dose of 
aftatoxin B1 (AFB) the resulting liver AFB-DNA adduct levels were directly proportional to dose. Earlier work 
also showed that after ten daily doses the AFB dose response relationship with y-glutamyl transpeptidase (GGT) 
positive preneoplastic foci measured at 3 months was sublinear, with a threshold at a dose of about 150 µg/kg 
body weight/day. The objective of this study is to determine the factors influencing the shift in AFB dose-
response between AFB-DNA adducts and GGT foci. Male Fisher 344 weanling rats were orally administered one 
or ten doses of AFB ranging from 50 to 350 µg/kg body weight/day. The animals were killed 2 or 24 h after the 
first AFB dose, or after the tenth AFB dose. The first and tenth doses were tritiated in these animals and 3H-
AFB-guanine adducts isolated from liver DNA were measured by HPLC. Another group was killed 3 months 
after receiving ten doses in order to measure GGT foci development. AFB-guanine adduct levels were directly 
proportional to dose after the first dose, but after the tenth dose were much lower in the 200-350 µg/kg groups 
than after a single dose. The GGT foci response confirmed earlier work concerning a sublinear response. Among 
the individual animals in the 200-350 µg/kg groups there was a positive relationship, after controlling for dose, 
between GGT foci development and weight gained both during dosing (P = 0.018) and also to a lesser extent 
during the early promotional period (P = 0.066). Enzyme activity levels of GGT in liver homogenates were higher 
in the highest dose groups and reflected biliary proliferation rather than histological GGT stained foci. Urinary 
levels of AFB metabolites changed proportions in the high dosage multiply dosed animals reflecting alteration in 
AFB metabolism or excretion. The differences between the linear adduct and the sublinear foci dose response 
curves may be the result of non adduct effects of higher multiple AFB doses on foci formation including acute 
cytotoxicity, altered AFB metabolism and disposition, enhanced weight gains, or shortened foci latency but not 
through enhanced guanine adduct levels. Other studies that showed a linear relationship between AFB dose and 
liver tumor development used continuous feeding of maximal doses an order of magnitude less than the lowest 
dose in this study and thus avoided acutely toxic effects. We hypothesize that liver tumor development may 
mirror foci response in a IO-dose AFB regimen with doses above 100 µg/kg due to acute toxicity effects
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Abstract • 
Earlier work in this laboratory and that carried out by others demonstrated that after a 
single dose of aftatoxin B1 (AFB) the resulting liver AFB-DNA adduct levels were directly 
proportional to dose. Earlier work also showed that after ten daily doses the AFB dose 
response relationship with y-glutamyl transpeptidase (GGT) positive preneoplastic foci 
measured at 3 months was sublinear, with a threshold at a dose of about 150 µg/kg body 
weight/day. The objective of this study is to determine the factors influencing the shift in 
AFB dose-response between AFB-DNA adducts and GGT foci. Male Fisher 344 weanling 
rats were orally administered one or ten doses of AFB ranging from 50 to 350 µg/kg body 
weight/day. The animals were killed 2 or 24 h after the first AFB dose, or after the tenth 
AFB dose. The first and tenth doses were tritiated in these animals and 3H-AFB-guanine 
adducts isolated from liver DNA were measured by HPLC. Another group was killed 3 
months after receiving ten doses in order to measure GGT foci development. AFB-guanine 
adduct levels were directly proportional to dose after the first dose, but after the tenth dose 
were much lower in the 200-350 µg/kg groups than after a single dose. The GGT foci 
response confirmed earlier work concerning a sublinear response. Among the individual 
animals in the 200-350 µg/kg groups there was a positive relationship, after controlling for 
dose, between GGT foci development and weight gained both during dosing (P = 0.018) and 
also to a lesser extent during the early promotional period (P = 0.066). Enzyme activity levels 
of GGT in liver homogenates were higher in the highest dose groups and reflected biliary 
proliferation rather than histological GGT stained foci. Urinary levels of AFB metabolites 
changed proportions in the high dosage multiply dosed animals reflecting alteration in AFB 
metabolism or excretion. The differences between the linear adduct and the sublinear foci 
dose response curves may be the result of non adduct effects of higher multiple AFB doses 
on foci formation including acute cytotoxicity, altered AFB metabolism and disposition, 
enhanced weight gains, or shortened foci latency but not through enhanced guanine adduct 
levels. Other studies that showed a linear relationship between AFB dose and liver tumor 
development used continuous feeding of maximal doses an order of magnitude less than the 
lowest dose in this study and thus avoided acutely toxic effects. We hypothesize that liver 
tumor development may mirror foci response in a IO-dose AFB regimen with doses above 
100 µg/kg due to acute toxicity effects.  
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1. Introduction
Cancer is a multistage disease. The initial insult is generally considered to be 
alteration of the DNA of a somatic cell. This alteration, if fixed through a cycle of 
cell division, may then be clonally expanded into a focus of cells of altered 
phenotype, then to a putatively neoplastic nodule, and finally progressing to tumor 
formation. Each of these stages is necessary but not sufficient for the subsequent 
stage. 
Aflatoxin B1 (AFB) is a potent hepatotoxin and hepatocarcinogen for certain 
experimental animal species [l]. AFB requires activation to the 8,9-epoxide to 
become carcinogenic. Other metabolic pathways yield primary and secondary 
metabolites of greatly reduced carcinogenic potency. The balance between activa- 
tion and metabolism is critical to the process of carcinogenesis. Although AFB is 
highly carcinogenic, it has been shown that a single high dose produces more liver 
necrosis and other acutely toxic events while multiple smaller doses produce more 
tumor response and less liver necrosis and acute toxicity [2]. 
The formation of AFB- DNA adducts is linearly dose dependent over a wide 
range of AFB doses and in various experimental models [3-7]. In contrast to these 
linear dose response curves for AFB-DNA adducts, we have previously observed 
a sublinear dose-response curve for putatively preneoplastic y-glutamyl transpepti- 
dase (GGT) positive foci 3 months after completion of 2 weeks of AFB dosing [8]. 
Foci only appear above a dose threshold of about 150 µg/kg body weight/day. 
Thus, even though there is a linear relationship between a single dose and adducts, 
there is a sublinear relationship between multiple doses and foci formation. 
There are several possible reasons for this disparity. Multiple AFB doses may 
yield disproportionately higher adduct levels at higher dosages through induction of 
AFB activating pathways. Multiple higher doses may also give rise to 
disproportionate levels of non-adduct effects such as increased liver necrosis, 
lower levels of DNA repair, or other non-genotoxic effects which promote 
carcinogenesis. Thus, the objective of this study was to determine possible 
mechanisms for the change in dose response curves between adducts and foci. 
2. Methods
2.1. Animals, chemicals, and diet 
Male Fisher-344 rats (50-75 g), purchased from Charles River Laboratories 
(Burlington, MA), were individually housed in suspended stainless steel cages 
with wire mesh bottoms. Upon receipt they were acclimated for 8 days in a room 
with controlled temperature, a 12-h photoperiodic cycle, and a relative humidity 
between 
40 and 60%. These conditions were  maintained throughout the study. Animals 
received food and water ad libitum. AFB was purchased from Calbiochem-
Behring (La Jolla, CA) and [G-3H]AFB (specific activity 10-20 Ci/mmol) from 
Moravek Biochemicals (City of Industry, CA). Aflatoxin P1 (AFP), and aflatoxin 
M 1 (AFM) were obtained from Sigma (St. Louis, MO). All other chemicals used 
in this study were of analytical or reagent grade. Purified AIN- 76A diet in 
pelleted form was prepared by Dyets, Inc. (Bethlehem, PA). 
2.2. Experimental protocol 
The rats were randomly assigned to treatment groups after acclimation (Fig. l 
). The treatments were planned on the basis of (a) dose of AFB administered 
(50, 100, 150, 200, 250, and 350 µg/kg body weight/day); (b) time of kill 
following dosing (2 h, 24 h, or 12 weeks after the last of ten doses), and (c) 
number of doses (one or ten). Groups for adduct quantification contained five 
animals each. Groups for GGT foci quantification contained ten animals each. 
Multiple-dose groups receiving 350 µg/kg body weight/day contained 40% more 
animals in anticipation of acute mortality. Both radioactive and non-radioactive 
AFB were prepared in tricaprylin for dosing. Sufficient crystalline  AFB for the 
entire experiment was dissolved in minimal chloroform and diluted in 
tricaprylin to a concentration of about 450 µg/ml. The chloroform was evaporated 
from the solution by stirring for 2 days in a fume hood. This stock solution was 
diluted with additional tricaprylin, and concentrated radioactive AFB in ethanol 
was added for the labeled doses, to the proper final concentrations such that the 
animals received tricaprylin at 1.0 ml/kg body weight. The absolute amount of 
radioactivity added to each labeled dosage was the same so that the specific 
activity was inversely proportional to the AFB concentration. Intubation 
commenced 8 days after receipt of  the animals. Groups A and B received single 
doses of tritiated AFB and were sacrificed 2 and 
24 h after dosing, respectively. The multiple-dose protocol groups (two adduct 
groups-groups C and D and one GGT foci group-group E) received  ten  daily 
doses over a 12-day period (with no dosing on the 2 middle days). The last dose 
for groups C and D were radiolabeled and animals were sacrificed 2 and 24 h after 
the last dose, respectively. Livers in all four adduct groups were immediately 
removed upon sacrificing and placed in ice-cold buffer (0.05 mol/l Tris-HCl pH 
7.0, 0.25 mol/l sucrose, 0.025 mol/l KCl, and 0.005 mol/l MgCl2). Animals in the 
GGT foci group were sacrificed 12 weeks after the last AFB dose. Two slices of 
liver were removed for each animal, frozen on dry ice, and stored at - 70°. The 
remainder of each liver was also stored at -70°. Two animals from each dosage of 
groups B and D were kept in metabolic cages during the overnight period 
between dosing and sacrifice. Complete 24 h collections of urine were obtained 
from groups B and D and were frozen at  - 70° until further analysis. 
2.3. Afiatoxin-DNA  adducts 
The method of Croy et al. [4] was used for the isolation of liver nuclei, the 
isolation of nuclear DNA, the hydrolysis of DNA, and the HPLC separation of 
AFB- DNA adducts. A Beckman model 334 HPLC (Fullerton, CA) with gradient 
capability and a Perkin-Elmer model LS95 UV-visible detector (Norwalk, CT) was 
used for adduct separation. The eluent was monitored at 360 nm and adducts were 
collected in l.0-ml fractions. Scintillation cocktail (10 ml) was added to each 
fraction  which  were  then  counted  in  a  Beckman  LS3133T  liquid  scintillation 
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counter. The AFB-N 7-guanine standard was prepared from an AFB-modified DNA 
sample according to the method of Groopman et al. [9]. The ring-open AFB-DNA 
adduct (8,9-dihydro-8-(2,6-diamino-4-oxo-3,4-dihydropyrimid-5-yl formamido)-9- 
hydroxyaflatoxin B1) was produced by first generating AFB- DNA according to 
Essigmann et al. [lO] then isolated by the method of Groopman et al [9]. The levels 
of the two products were summed. The original intention was to measure these two 
separately although an uncontrolled and random conversion of N7-guanine to the 
open-ring derivative during the DNA isolation and hydrolysis steps prohibited 
individual quantification [9]. Thus, the summation of both was used as a reliable 
measure  of total AFB- DNA adducts. 
 
2.4. Histochemical  GGT positive  liver foci 
 
The method of Dunaif and Campbell [8] was used. Four liver sections were 
prepared and stained for GGT according to the method of Rutenburg et al. [ll]. 
Foci were counted and average diameters were measured by light microscopy. The 
fraction of liver occupied by foci (as expressed as parts per million of liver volume) 
and the number of foci per cubic centimeter were obtained by mathematical models 
described by Campbell et al. [12] and Nychka et al. [13]. 
 
2.5. Biochemical liver homogenate GGT 
 
This method was a combination of the methods of Misslbeck et al. [14] and 
Cameron et al. [15]. A liver sample was prepared by homogenizing in a Polytron® 
homogenizer (Brinkman Instruments, Westbury, NY) about 0.5 g of frozen liver 
and 4 parts 0.1 mol/l Tris-HCI pH 8.0 (at 37°C). A 0.5-ml aliquot was placed in 
three 15 ml Corex® tubes in a shaking water bath at 37°C. Trichloroacetic acid (2.0 
ml of an 11% solution) was added immediately to one tube. After the tubes were 
warmed to temperature, 1.5 ml of substrate solution was added. The substrate 
solution was 4 mmol/l y-glutamyl-p-nitroanilide prepared daily by dissolution at 
60°C in a 50 mmol/l solution of glycylglycine and 0.1 mol/l Tris-HCI pH 8.0 (at 
37°C). The reaction tubes were agitated slowly for 20 min in the water bath. The 
reaction was stopped with the addition of trichloroacetic acid. The tubes were 
centrifuged at 3500 rpm in a SB-14 rotor in a Sorvall RC-5B centrifuge (Dupont, 
Wilmington, DE) for 20 min. After centrifugation 2.0 ml of supernatant was 
transferred to a 12 x 100 mm Pyrex® tube. To each tube 1.0 ml of 0.1% NaN02 was 
added. After 3 min 1.0 ml of 1.0% ammonium sulfamate was added. After another 
3 min, 1.0 ml of 0.052% naphthylethylenediamine was added and the tubes were 
shaken vigorously. The tubes were read immediately in the Beckman Instruments 
(Fullerton, CA) model 25 spectrophotometer at 540 nm. The activity was calculated 
using an molar absorptivity coefficient of 6218 for the reaction product, p-ni- 
troanilide. If the activity was too high, a diluted sample of liver homogenate was 
used to repeat the assay. The protein content was determined and specific activity 
was calculated. Activity was expressed as µmol/min/mg protein. 
 
 
 
2.6. Urinary acids 
 
This method is a major modification of the method of Mattiuz et al. [16] for 
separating and quantifying an extensive profile of urinary acids. A urine sample was 
centrifuged in the Eppendorf micro-centrifuge (Brinkman  Instruments,  Westbury, 
NY) in a 1.5 ml Eppendorf capsule. An  amount of urine equivalent to the urinary 
excretion of 2 g of body weight was diluted to 200 µl with water. Then 100 µl was 
injected on the HPLC.  The HPLC was a Beckman model 334 with detectors and 
integrators in-line. The first was a Perkin-Elmer LS95 UV-Visible  detector  (Nor- 
walk, CT) set at 280 nm attached to a Spectra Physics WINner® integration system 
(including  a  S/P4290  integrator)  (San  Jose,  CA). The  second  was  a  Bioanalytical 
Systems (West Lafayette, IN) electrochemical detector set at  + 900 mV attached to 
a Hewlett Packard model 3396 integrator (Palo Alto, CA). The third  was  a 
Beckman filter fluorometer with fluorescamine filters attached to a Hewlett Packard 
model  3390A integrator.  The column was a Phenomenex  (Torrance,  CA) Ultramex 
5 µm Cl8 250 x 4.6 mm with a 2-µm Upchurch (Oak Harbor, WA) in-line 
prefilter. The autosampler was a Perkin-Elmer model ISSlOO with a 250-µl sample 
loop. The starting solvent was 0.2 mol/l sodium phosphate buffer pH 2.3 and the 
flow rate was 1.0 ml/min. The timed gradient program was as follows. Injections 
were made at time 0. 
 
 
Program time Gradient of acetonitrile Duration of gradient 
(min) ( %as v/v) (min) 
 
0 0 6 
6 0 -6 59 
65 6 - l l 18 
83 11 -13 IO 
93 13- 20 21 
113 20 -35 15 
128 35 - 70 3 
148 70 -0 7 
200 Ready for next injection  
 
Each chromatogram was 145 min long. About 165 peaks eluted. 
 
2.7. . Urinary AFB products 
 
When the urine samples from AFB dosed animals  (Groups B and D) were 
subjected to the urinary acid analysis about a dozen small fluorescent peaks 
appeared late in the chromatogram (113-135 min). These same peaks contained 
radioactivity hence  it was concluded that these were aflatoxin (AF)-containing 
peaks. Authentic AF standards were run under identical conditions. AFM and AFP 
 
 
Table  I 
Animal growth rates during specific study periods and terminal body weightsa 
 
AFB dose Dosing Recovery Post-recovery Terminal  weight 
(µg/kg) (days 1-12) (days 13-23) (days 24-99)  
 
50 
JOO 
4.05 ± 0.43a 
3.89 ± 0.47a.b 
3.76 ± 0.6oa 
3.74 ± 0.79" 
1.90 ± o.19a 
J .98 ± 0.26a.b 
326 ± 17a 
327 ± 24a 
150 3.59 ± 0.64b.c 3.47 ± 0.54a 1.98 ± 0.23•.b 321 ± 24" 
200 3.61 ± 0.53b.c 3.62 ± 0.50" 2.02 ± 0.15"·b 330 ± 14" 
250 3.34 ± 0.54c 3.80 ± 0.56" 2.05 ± O. J2•·b 332 ± 13• 
350 2.94 ± 0.59d 2.88 ± 0.71b 2.10 ± 0.3J b 317 ± 30" 
Regrb P $;0.00 I P =0.002 P =0.027 P =0.4 
•Growth  rates  (g/day ± S.D.) represent  average  growth  rates  over  each  study  period.  Significantly 
different values (P<0.05) within a column are denoted by different letters. 
b The probability associated with a linear model of weight gain or terminal weight vs/ AFB dose. 
 
co-eluted in one peak. Other aflatoxin-containing peaks were  not identified. In 
order to confirm the identity of the combined AFM and AFP (AFM/P) peak, a 
modification of the method of Groopman et al. [17] was utilized. Samples and 
standards were prepared and injected into the HPLC in the same manner as for the 
urinary acids. 
 
2.8. Other analytical methods 
 
RNA was determined by the orcinol assay described by Ceriotti [18]. The method 
used to check the protein contamination of the DNA was that of Lowry et al. [19]. 
Liver homogenate protein determination for the GGT assay was with the Sigma 
Diagnostic Kit P5656. DNA was determined by the method of Burton  [20]. All 
statistical procedures including ANOVA, Student's t-tests, and regression analysis, 
were performed with the MINITAB 6.1.1 software package (State College, PA) 
implemented on a personal computer. 
 
 
3. Results 
 
AFB dosing caused a linear depression in weight gain with increasing AFB dose 
(R = -0.576, P < 0.001) (Table 1). This dose-dependent depression continued 
through the 1 week recovery period following dosing (P = 0.002). However, from 
the end of the recovery period until the end of the study, the higher dose animals 
gained significantly more weight than their lower dose counterparts. At the end of 
the study, body weights were not significantly related to dose. 
Fig. 2 shows the dose-response relationship of AFB-DNA adducts for the four 
adduct groups. A significant linear relationship existed between a single AFB dose 
and adducts both in animals killed 2 h post-dose (Fig. 2A) (R = 0.89) and in 
animals killed 24 h post-dose (Fig. 2B) (R = 0.92). The level of adducts was reduced 
 
 
 
by about half, between 2 and 24 h, in all dosage groups. Somewhat similar results 
were observed for the animals administered nine doses before the radiolabeled tenth 
dose (groups C and D) except that adduct levels were substantially reduced at the 
two highest dosage levels (Fig. 2C, D) when compared with the single dose animals 
(groups A and B) (P < 0.002). Furthermore, the dose-response slope also was 
considerably flattened by the prior administration of nine cold AFB doses. Adduct 
levels were unchanged, at the two lowest dosage levels, between the first and the 
tenth doses (P > 0.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 24-h urinary excretion of total AFB products per gram of body weight (Fig. 3) 
produced a linear function of dose. Groups B and D were similar in their dose-
response (R = 0.95 for combined groups). The percentage of total radioactivity for 
each HPLC AFB metabolite peak varied significantly with dose and group. For 
example, the percentage of total radioactivity in the AFM/P peak (Fig. 4} showed 
a  flat  dose-response  relationship  in  group  B  (R = 0.13),  but  a  positive  linear 
 
Table 2 
Aflatoxin B 1 dose-response of y-glutamyl transpeptidase positive foci and y-glutamyl transpeptidase 
specific activity• 
 
AFB dose 
(µg/kg) 
Specific activity 
(µmol/min/mg 
protein) 
Foci incidence Foci number 
(no./cm3 
) 
Foci diameter 
(µm) 
Foci volume 
(ppm) 
50 10 ± 4" 5/10 10 ± 16" 108 ± 52• 15 ± 21" 
100 12 ± 3•.b 4/10 10 ± 15" 99 ± 42" 16 ± 28" 
150 12 ± 3a.b 7/10 24 ± 21· 116 ± 56" 37 ± 46" 
200 14 ± 2a,b 5/10 10 ± 18° 207 ± 73a.b 115 ± 180" 
250 21 ± 7b 6/10 13 ± 16" 147 ± 150•,b 24 ± 36" 
350 37 ± 19c 10/14 25 ± 24° 233 ± 96b 678 ± 1008b 
• Values are group means ± S.D. Significantly different values within a column are denoted by different 
letters. For foci volume, differences were tested with fourth-root transformed values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
response with AFB dose in group D (R = 0.63). A negative linear response was seen 
with other radioactive peaks (data not shown) after ten doses. Thus, among the 
multiply dosed animals receiving higher doses, AFM/P commanded an increasing 
share of the urinary AFB metabolites, at the expense of the remaining AFB 
metabolites. The limited group D data may also suggest a curvilinear response with 
a maximum percentage excretion at the 250 µg dose. 
At lower AFB doses GGT specific activities were about 10-12 µmol/min/mg 
protein, while at the two highest doses specific activities were elevated (Table 2). 
Histological observations were made of more extensive non-focal GGT staining, 
particularly biliary hyperplasia, in the higher dose groups. 
The number of foci-bearing animals in each group was not significantly related to 
AFB dose (P = 0.13 with weighted logistic regression). Foci  number  also did  not 
vary with dose. The mean diameter of foci among foci-bearing animals was 
positively and linearly related to dose although the difference between the highest 
and lowest group was small. Foci volume exhibited highly skewed within group 
distributions  and  showed an  irregular  but  positive  dose-response  relationship  (Fig. 
5). Transformation of these data to the fourth root produced more normally 
distributed residuals and also a more linear dose-response. There appeared to be a 
dose threshold between about 150 and 250 µg/kg. 
In the 50-150 µg/kg groups there was no correlation between body weight gain 
and any measure  of foci response among individual rats. In the 200-350 µg/kg 
groups there was a positive correlation between G'GT foci volume, after adjusting 
 
 
for dose, and body weight gained during the dosing period (P = 0.018) and also to 
a lesser extent with weight gained during the post-recovery period (P = 0.066). The 
relationship between weight gained during the dosing period and volume of foci 
was due primarily to weight gained during the last 2 days of dosing. Weight gained 
during dosing was also weakly correlated with number of foci (P = 0.086) but not 
with foci diameter. The relationship of foci volume with compensatory weight gain 
during the post recovery period was primarily due to weight gained during the third 
 
week post-dosing. The post-dosing weight gain was also correlated with foci 
diameters (P = 0.038) but not with number of foci. 
 
 
4. Discussion 
 
Two methodological shortcomings are evident in this report: the HPLC quantita- 
tion of AFB-N7-guanine adducts and the HPLC separation of urinary AFB 
metabolites. Although the high variability of the adduct data must certainly be 
derived, in part, from the in vitro degradation of the closed ring N7-adduct to the 
open-ring form [9], we are confident in our summed data because they are in 
agreement with our earlier results with single dose adducts [3]. The development of 
the urinary acids method was incidental to this original project and the clear 
resolution of many AFB-containing peaks was unanticipated. Our inability to 
identify all of the urinary peaks or to resolve the excreted AFM and AFP does not 
detract from our simple assertion that these data probably reflect altered 
metabolism or disposition of AFB after multiple high doses of AFB. 
 
 
 
 
Earlier research demonstrated a linear dose-response relationship for AFB-in- 
duced rat liver DNA adducts measured 2 h after a single dose in the range from l 
ng/kg to 1 mg/kg [3,7,21,22]. We confirm these earlier findings in the range of 
50-350 µg/kg. Our finding of a 50% decrease in adducts at 2 and 24 h post-dosing 
is less than was found by Croy et al., with 600 µg/kg administered i.p. [23]. 
However, at 3 h post-dosing, adduct levels from an oral dose are less than from an 
i.p. dose [24]. Other workers have measured the cumulative levels of DNA adducts 
after multiple dosing [7,21,23] and found an increase with the number of doses or 
the  size of  dose.  In  this  study  only  the  tenth  dose  was  radioactive  hence  we 
measured the effect of nine previous doses on the DNA adduction of the last dose. 
Prior exposure to high  levels (250-350 µg/kg/day) of AFB reduced  by about 
two-thirds adducts formed by the last dose compared to the first. Schrager et al. 
[25] measured AFB-N7-guanine adducts after ten doses of about 200-250 µg/kg/ 
day and found about a 50% decrease in accumulated adducts compared to adduct 
levels after a single dose. 
Previous studies have shown considerable variability in AFB-induced foci re- 
sponse among identically treated rats [8,14,26,27]. The source of this variability is 
unknown but may be compensated for by a large number of animals per group. In 
spite of the decrease in adducts with multiple higher AFB doses, we observed a 
curvilinear increase in GGT foci at doses above about 150 µg/kg was supported by 
the results of this study in conjunction with earlier finding in this laboratory [8]. 
This suggests that factors other than specific AFB-DNA adduct formation en- 
hance foci, and possibly tumor, development at higher multiple doses. Much recent 
research has elucidated an apparent linear relationship between AFB- DNA ad- 
ducts and tumor formation. Previous work with a limited number of rats and 
impure AFB preparations showed an essentially linear relationship between loga- 
rithm of dose and liver tumor incidence on a probit scale [28,29]; a similar finding 
was reported in trout [30]. Bechtel [31] has shown that rats and trout share an 
identical linear dose-response relationship between adduct levels and tumors. While 
AFB, aftatoxicol (a metabolite of AFB), AFM, and aftatoxicol M 1 have different 
potencies to cause liver tumors in trout, Bailey showed that when comparing AF-
DNA adducts and liver tumor response, the dose-response lines are nearly 
identical [32,33]) when expressed on a molecular basis. 
There are two differences between these earlier studies showing linear dose 
response relationship and these findings showing a curvilinear response. Here, we 
used a 10-dose regimen and a higher dose level. The highest dose in the Wogan et 
al., tumor study [28], fed continuously, was about 15 µg/kg/day, using the dietary 
to body weight dosing conversion of Zeise et al. [34], compared to our lowest dose 
of 50 µg/kg body weight/day. The highest dose in the Bechtel study [31] was a 
continuous feeding of about 3 µg/kg body weight/day. Poirier and Beland com- 
pared nine biological models of adduct-tumor dose-responses and found only five 
that were linear [35]. They concluded that nonlinearity was a consequence of 
tissue-specific phenomena such as metabolic activation, cell proliferation, and/or 
cytotoxicity. These effects are accentuated at higher, more acutely toxic, doses. Lutz 
has suggested that, although DNA binding may be proportional to dose, cytotoxi- 
 
 
city-induced cell division induced disproportionately at higher doses may enhance 
tumor development [36,37]. Eaton and Gallagher also suggest that tumorigenic 
response does not necessarily follow linearity at all doses because of the cytotoxic 
effects of AFB at higher doses [38]. 
We observed suggestive evidence of all three enhancing factors described by 
Poirier and Beland [35]. The changing patterns of urinary AFB metabolites reflects 
an increased excretion of less active metabolites (AFM or AFP) at high doses 
possibly through induction of altered metabolic pathways in the liver. These 
findings are in agreement with the less than expected levels of AFB-DNA adducts 
in these groups. Among multiply high dose animals there is a correlation between 
weight gain, a crude reflection of cellular proliferation, and foci development. The 
homogenate GGT activity levels were highest in animals with clearly stained biliary 
proliferation, a result of fibrotic regeneration from cytotoxicity. 
In animal tumorigenesis models on nitrosamines, an inverse relationship between 
dose and time-to-response has been observed for foci [39] and tumor [40] formation. 
Animals administered low doses of a carcinogen take longer to develop foci than 
animals given higher doses. The possible carcinogenic-enhancing mechanisms at 
high doses observed in our study could shorten the time required for foci 
development, thereby enhancing the apparent threshold-dose nature of the dose-
response curve. 
In light of these and other findings, we suggest that AFB-induced GGT liver foci, 
and liver tumors, develop in a linear manner to multiple or continuous dosing at 
sub-toxic levels (below about 100-150 mg/kg). Above this level foci (and possibly 
tumors) develop in a curvilinear exponential manner at higher toxic AFB levels due 
to non-adduct metabolic, proliferative, and cytotoxic effects in spite of having 
reduced DNA adduct levels that were similar to adduct levels at much lower less 
acutely toxic doses. 
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